Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.
Lüftinger R, Zubarovskaya N, Galimard JE, Cseh A, Salzer E, Locatelli F, Algeri M, Yesilipek A, de la Fuente J, Isgrò A, Alseraihy A, Angelucci E, Smiers FJ, La La Nasa G, Zecca M, Fisgin T, Unal E, Kleinschmidt K, Peters C, Lankester A, Corbacioglu S; EBMT Pediatric Diseases, Inborn Errors Working Parties.
Lüftinger R, et al.
Ann Hematol. 2022 Mar;101(3):655-665. doi: 10.1007/s00277-021-04732-4. Epub 2022 Jan 9.
Ann Hematol. 2022.
PMID: 34999929